Pulmozyme Side Effects
Generic name: dornase alfa
Note: This document contains side effect information about dornase alfa. Some of the dosage forms listed on this page may not apply to the brand name Pulmozyme.
Some side effects of Pulmozyme may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.
For the Consumer
Applies to dornase alfa: inhalation solution
If you experience any of the following serious side effects while taking dornase alfa (the active ingredient contained in Pulmozyme) seek emergency medical attention or contact your doctor immediately:
-
an allergic reaction (difficulty breathing; closing of the throat; swelling of the lips, tongue, or face; or hives);
-
increased difficulty breathing;
-
chest pain; or
-
fever.
Less serious side effects may be more likely to occur with the use of dornase alfa. Talk to your doctor if you experience any of the following side effects:
-
voice alteration;
-
sore throat;
-
rash;
-
laryngitis;
-
eye redness, irritation, or inflammation; or
-
nasal stuffiness or discharge.
Side effects other than those listed here may also occur. Talk to your doctor about any side effect that seems unusual or that is especially bothersome.
For Healthcare Professionals
Applies to dornase alfa: inhalation solution
General
Dornase alfa (the active ingredient contained in Pulmozyme) has been generally well tolerated. Dose ranging studies employing daily dosages as high as 40 mg revealed no significant adverse effects. The most common adverse reactions have been respiratory in nature and included pharyngitis (36% to 40% versus 33% with placebo, n=968), voice alteration or hoarseness (12% to 16% versus 7%), laryngitis (3% to 4% versus 1%), dyspnea and increase in cough. Rash has also occurred frequently (10% to 12% versus 7%).
Many of these adverse reactions have been difficult to distinguish from symptoms of the underlying disease. Hoarseness and pharyngitis have been shown to be dose-related in one study. The hoarseness was transient and regressed after a 3 week period. Withdrawal rates in clinical trials have been similar between active and placebo groups.
Cardiovascular
Cardiovascular side effects have included chest pain, which has been reported in 18% to 21% of patients receiving dornase alfa (the active ingredient contained in Pulmozyme) versus 16% with placebo.
Ocular
Ocular side effects have included conjunctivitis which has been reported in 4% to 5% of patients receiving dornase alfa (the active ingredient contained in Pulmozyme) versus 2% with placebo.
Hypersensitivity
Hypersensitivity side effects have included a small percentage of patients who developed serum antibodies to the drug, but no anaphylaxis or severe allergic reactions have been reported. The clinical relevance of the rhDNase antibodies is presently unknown. No immunoglobulin E antibodies have been detected. exposed to the drug during clinical trials
Other
Special face masks are not needed for caregivers involved with the administration of dornase alfa (the active ingredient contained in Pulmozyme) Studies have shown that the passive airborne exposure is well below the clinical dose during administration and nondetectable 15 to 45 minutes after treatment.
More Pulmozyme resources
- Pulmozyme Prescribing Information (FDA)
- Pulmozyme Monograph (AHFS DI)
- Pulmozyme Advanced Consumer (Micromedex) - Includes Dosage Information
- Pulmozyme MedFacts Consumer Leaflet (Wolters Kluwer)
- Pulmozyme Consumer Overview
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.


